Eric Sachetta Acquires 37,537 Shares of Sensus Healthcare (NASDAQ:SRTS) Stock

Sensus Healthcare, Inc. (NASDAQ:SRTS) Director Eric Sachetta acquired 37,537 shares of Sensus Healthcare stock in a transaction that occurred on Friday, August 28th. The shares were purchased at an average price of $3.44 per share, with a total value of $129,127.28. Following the transaction, the director owned 267,480 shares of the company’s stock, valued at $920,131.20. The trade was a 16.32% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Eric Sachetta also recently made the following trade(s):

• On Monday, August 31st, Eric Sachetta bought 27,304 shares of Sensus Healthcare stock. The stock was purchased at an average cost of $3.54 per share, for a total transaction of $96,656.16.
• On Thursday, August 27th, Eric Sachetta purchased 10,925 shares of Sensus Healthcare stock. The shares were acquired at an average cost of $3.18 per share, with a total value of $34,741.50.
• On Wednesday, August 26th, Eric Sachetta acquired 9,708 shares of Sensus Healthcare stock. The stock was acquired at an average price of $3.29 per share, for a total transaction of $31,939.32.
• On Monday, August 24th, Eric Sachetta acquired 34,697 shares of Sensus Healthcare stock. The stock was acquired at an average cost of $3.25 per share, for a total transaction of $112,765.25.

Sensus Healthcare Trading Up 3.4%

NASDAQ SRTS traded up $0.12 during trading hours on Monday, hitting $3.64. 102,018 shares of the company’s stock traded hands, compared to its average volume of 65,130. Sensus Healthcare, Inc. has a 52 week low of $2.66 and a 52 week high of $5.49. The firm has a market capitalization of $59.91 million, a P/E ratio of -3.87 and a beta of 1.10. The business’s fifty day moving average price is $3.05 and its two-hundred day moving average price is $3.51.

Sensus Healthcare (NASDAQ:SRTS) last issued its quarterly earnings results on Thursday, August 13th. The company reported ($0.53) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.41). Sensus Healthcare had a negative return on equity of 21.57% and a negative net margin of 88.45%.The business had revenue of $2.29 million for the quarter, compared to analysts’ expectations of $4.60 million.

Institutional Trading of Sensus Healthcare

Hedge funds have recently modified their holdings of the company. Pacific Ridge Capital Partners LLC lifted its position in Sensus Healthcare by 21.8% during the fourth quarter. Pacific Ridge Capital Partners LLC now owns 698,634 shares of the company’s stock valued at $2,781,000 after purchasing an additional 125,245 shares during the last quarter. Geode Capital Management LLC grew its position in Sensus Healthcare by 3.5% in the 4th quarter. Geode Capital Management LLC now owns 158,240 shares of the company’s stock valued at $630,000 after acquiring an additional 5,316 shares during the last quarter. Sachetta LLC boosted its stake in shares of Sensus Healthcare by 6.8% during the fourth quarter. Sachetta LLC now owns 148,508 shares of the company’s stock valued at $591,000 after purchasing an additional 9,500 shares during the period. Greenline Wealth Management LLC purchased a new stake in shares of Sensus Healthcare during the fourth quarter valued at $513,000. Finally, North Star Investment Management Corp. purchased a new position in Sensus Healthcare in the 1st quarter worth about $500,000. 25.30% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on SRTS. Citigroup reiterated a “buy” rating on shares of Sensus Healthcare in a research note on Friday, May 8th. Lake Street Capital lowered their price target on shares of Sensus Healthcare from $4.50 to $4.00 and set a “buy” rating on the stock in a report on Friday, August 14th. Alliance Global Partners reiterated a “buy” rating on shares of Sensus Healthcare in a research report on Monday, August 17th. Weiss Ratings cut shares of Sensus Healthcare from a “sell (d)” rating to a “sell (d-)” rating in a research note on Tuesday, August 18th. Finally, Wall Street Zen downgraded shares of Sensus Healthcare from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 9th. Four investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $5.83.

About Sensus Healthcare

Sensus Healthcare, Inc is a medical technology company specializing in the development, manufacture and commercialization of superficial radiation therapy (SRT) systems. The company’s SRT devices utilize low-energy X-rays to treat a range of dermatological and oncological conditions, most notably non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma, as well as benign lesions including keloids. By delivering targeted radiation to superficial tissue layers, Sensus Healthcare’s systems aim to provide an alternative to surgical excision or systemic therapies, offering clinicians a non-invasive treatment option for eligible patients.

The company’s flagship products include the SRT-100™ and SRT-100+™ platforms, which feature handheld applicators, adjustable energy settings and integrated safety controls.